Eli Lilly and Company
Company & revenue
About Eli Lilly and Company
Financial breakdown: year ended 2025-12-31 · Research updated Oct 2, 2026
Who they are
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.
How they make money
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products. The company generates revenue primarily through product sales to wholesalers, pharmacies, and hospitals, as well as through collaboration and other licensing arrangements.
Products & services
Human pharmaceutical products including treatments for cardiometabolic health, oncology, immunology, and neuroscience, with key products including Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance.
Brands & revenue mix
Cardiometabolic health product; revenue combined with Zepbound for reporting purposes.
Separate brand revenue is not available in this research.Source
Cardiometabolic health product; revenue combined with Mounjaro for reporting purposes.
Separate brand revenue is not available in this research.Source
Cardiometabolic health product.
Separate brand revenue is not available in this research.Source
Cardiometabolic health product (includes Glyxambi, Synjardy, and Trijardy XR).
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Calculated from reported segment revenue. Percentages use consolidated company revenue unless a different denominator is stated.
Geographic revenuePREMIUM
Calculated from reported segment revenue. Percentages use consolidated company revenue unless a different denominator is stated.
Customer types
Disclosed major customersPREMIUM
Customer concentrationPREMIUM
In 2025, three U.S. wholesale distributors (McKesson, Cencora, and Cardinal Health) each accounted for between 16 percent and 24 percent of consolidated revenue.
Suppliers, materials & equipmentPREMIUM
- Contract manufacturing organizations — Entities providing manufacturing support for current and prospective products; specific supplier companies are unnamed.Source
- Artificial intelligence vendors — Third-party providers of AI technology for drug discovery and other business initiatives; specific supplier companies are unnamed.Source
Business relationships & partnershipsPREMIUM
- Boehringer Ingelheim — A long-standing collaboration for the development and commercialization of diabetes products including Jardiance.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
42
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
82
Strong
Financial Strength
57
Business Quality / Moat
100
Management
95
Growth Quality
86
Risk / Durability
85
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
50
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
59/100
Building Historical Record
Model Score 59/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for LLY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can LLY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is LLY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is LLY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify LLY's current valuation?
Essential Investment Snapshot
Wall Street Score
42
Opportunity Score
50
Market Cap
$1.08T
P/E Ratio
38.5
EPS
$29.89
52-Week High
$1292.65
52-Week Low
$783.85
Beta
0.50
Intrinsic Value
$1150.76
Analyst Target
$1376.00
Shares Outstanding
898.0M
Total Revenue
$79.67B
Total Debt
$54.91B
Dividend Yield
0.61%
Liquidation Value / Share
$37.73
Annual Dividend
$6.92
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for LLY
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on LLY.
What the Bulls Say
- +Strong portfolio of cardiometabolic health products.
- +Significant investment in pharmaceutical research and development.
- +Material partnership/catalyst: A long-standing collaboration for the development and commercialization of diabetes products including Jardiance.
- +Material partnership/catalyst: Entities providing manufacturing support for current and prospective products.
What the Bears Say
- −Cybersecurity and IT system vulnerabilities.
- −Risks associated with the use of artificial intelligence technologies.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
40
Jul 24, 2026
Change
+1.9
points
Current Score
42
Oct 1, 2026
Category Changes
LLY increased 1.9 points because Revenue improved by 6.2 points, Capital improved by 2 points, Valuation improved by 10.3 points.
Positive Contributors
- + Revenue improved by 6.2 points
- + Capital improved by 2 points
- + Valuation improved by 10.3 points
- + Buffett improved by 2.3 points
Projected Score
Projected Score
44
Projected Change
+2.4%
Preliminary comparable-period financial changes suggest improvement of approximately 2.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$1142.85
Intrinsic Value
$1150.76
Difference
−$7.91
-0.7% vs IV
Margin of Safety
0.7%
Related Companies
Drug Manufacturers - GeneralNews
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial